ALBIREO PHARMA INC's ticker is ALBO and the CUSIP is 01345P106. A total of 84 filers reported holding ALBIREO PHARMA INC in Q2 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $2,468,000 | -6.0% | 70,000 | 0.0% | 0.16% | -17.0% |
| Q4 2020 | $2,626,000 | -21.3% | 70,000 | -30.0% | 0.19% | -35.2% |
| Q3 2020 | $3,337,000 | -16.0% | 100,000 | -33.3% | 0.29% | -18.1% |
| Q2 2020 | $3,974,000 | +61.8% | 150,000 | 0.0% | 0.35% | +35.1% |
| Q1 2020 | $2,456,000 | -3.4% | 150,000 | +50.0% | 0.26% | +40.1% |
| Q4 2019 | $2,542,000 | -4.4% | 100,000 | -24.8% | 0.19% | -7.9% |
| Q3 2019 | $2,660,000 | -38.0% | 133,000 | 0.0% | 0.20% | -35.6% |
| Q2 2019 | $4,288,000 | -11.3% | 133,000 | -11.3% | 0.32% | -11.8% |
| Q1 2019 | $4,832,000 | +57.6% | 150,000 | +20.0% | 0.36% | +41.1% |
| Q4 2018 | $3,066,000 | -25.6% | 125,000 | 0.0% | 0.25% | -8.0% |
| Q3 2018 | $4,120,000 | -7.2% | 125,000 | 0.0% | 0.28% | -5.8% |
| Q2 2018 | $4,438,000 | +49.2% | 125,000 | +36.9% | 0.29% | +46.7% |
| Q1 2018 | $2,974,000 | – | 91,323 | – | 0.20% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Prosight Management, LP | 514,082 | $11,973,000 | 7.17% |
| Privium Fund Management B.V. | 379,117 | $8,959,000 | 1.78% |
| Birchview Capital, LP | 113,000 | $2,632,000 | 1.70% |
| Sio Capital Management, LLC | 213,913 | $4,982,000 | 1.50% |
| Perceptive Advisors | 4,720,278 | $109,936,000 | 0.85% |
| Chicago Capital, LLC | 849,239 | $19,779,000 | 0.74% |
| APOGEM CAPITAL LLC | 38,601 | $899,000 | 0.59% |
| Samsara BioCapital, LLC | 100,000 | $2,329,000 | 0.45% |
| Artal Group S.A. | 600,000 | $13,974,000 | 0.38% |
| RICE HALL JAMES & ASSOCIATES, LLC | 458,011 | $10,667,000 | 0.38% |